Michelle LaSpaluto
Directeur Financier/CFO chez CHIMERIX, INC.
Fortune : 98 900 $ au 30/04/2024
Profil
Michelle LaSpaluto is currently the Chief Financial Officer at Chimerix, Inc. since 2023.
Previously, she worked as the Senior Director-Accounting at AlphaVax, Inc. from 2000 to 2011.
Ms. LaSpaluto completed her undergraduate degree at Michigan State University and holds an MBA from East Carolina University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CHIMERIX, INC.
0,12% | 14/02/2024 | 110 999 ( 0,12% ) | 98 900 $ | 30/04/2024 |
Postes actifs de Michelle LaSpaluto
| Sociétés | Poste | Début |
|---|---|---|
| CHIMERIX, INC. | Directeur Financier/CFO | 01/12/2023 |
Anciens postes connus de Michelle LaSpaluto
| Sociétés | Poste | Fin |
|---|---|---|
AlphaVax, Inc.
 AlphaVax, Inc. Pharmaceuticals: MajorHealth Technology AlphaVax, Inc. involves in clinical-stage biopharmaceutical company. It develops vaccine technology bio products. The firm products include Alphavax and pipleline bio products. It focuses on commercial potential of its alphavaccine vector technology in cancer immunotherapy. The company was founded in 1997 and is headquartered in Durham, NC. | Comptroller/Controller/Auditor | 01/06/2011 |
Formation de Michelle LaSpaluto
| East Carolina University | Masters Business Admin |
| Michigan State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CHIMERIX, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
AlphaVax, Inc.
AlphaVax, Inc. Pharmaceuticals: MajorHealth Technology AlphaVax, Inc. involves in clinical-stage biopharmaceutical company. It develops vaccine technology bio products. The firm products include Alphavax and pipleline bio products. It focuses on commercial potential of its alphavaccine vector technology in cancer immunotherapy. The company was founded in 1997 and is headquartered in Durham, NC. | Health Technology |
